Menu
← Oncology Approval Tracker
FDA DECISION ·
Opdivo
nivolumab · Bristol Myers Squibb
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
The adjuvant indication after complete resection of melanoma with nodal involvement or metastatic disease expanded to patients aged 12 or older.
LAMPGEN ANALYSIS
Why it matters
The pediatric supplement extended a postsurgical use distinct from active unresectable disease.
What research teams should watch
Document nodal or metastatic involvement and complete resection. The subsequent stage IIB and IIC indication was a separate action.
PRIMARY RECORDS